[DOI] [PMC free article] [PubMed] [Google Scholar] 84.Hoseini A., Namazi G., Farrokhian A., Reiner ., Aghadavod E., Bahmani F., Asemi Z
Read source Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss
Available at: Accessed
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
It has been shown to upregulate pathways tied to collagen and glycosaminoglycan synthesis, modulate metalloproteinase (MMP) and tissue inhibitor of metalloproteinases (TIMP) balance, and support antioxidant effects, thereby contributing to matrix organization and structural stability in research settings